Lisanti Capital Growth LLC acquired a new position in shares of SiBone (NASDAQ:SIBN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 168,525 shares of the company's stock, valued at approximately $2,364,000. Lisanti Capital Growth LLC owned approximately 0.40% of SiBone as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Johnson Investment Counsel Inc. bought a new stake in SiBone during the 1st quarter worth approximately $148,000. Elevation Point Wealth Partners LLC purchased a new position in shares of SiBone in the 1st quarter worth approximately $204,000. Charter Oak Capital Management LLC bought a new position in shares of SiBone in the first quarter valued at approximately $337,000. Rhumbline Advisers grew its holdings in shares of SiBone by 3.6% in the first quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after acquiring an additional 2,100 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after acquiring an additional 3,867 shares in the last quarter. 98.11% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
SIBN has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of SiBone in a report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of SiBone in a report on Tuesday, May 6th. Finally, Truist Financial upped their target price on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th.
Check Out Our Latest Stock Report on SiBone
Insider Activity at SiBone
In other SiBone news, insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now owns 284,555 shares in the company, valued at $4,026,453.25. This represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares in the company, valued at approximately $3,462,574.92. This represents a 1.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,942 shares of company stock worth $1,734,203. Insiders own 4.00% of the company's stock.
SiBone Price Performance
SiBone stock opened at $18.43 on Friday. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21. The business's 50 day simple moving average is $17.37 and its 200 day simple moving average is $16.00. The company has a market cap of $785.49 million, a price-to-earnings ratio of -28.80 and a beta of 0.94.
SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. The business had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. Sell-side analysts forecast that SiBone will post -0.78 EPS for the current year.
SiBone Company Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
See Also
Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SiBone (NASDAQ:SIBN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
